LEAD 472
Alternative Names: LEAD-472Latest Information Update: 16 Sep 2022
At a glance
- Originator LeadArtis
- Class Antineoplastics; Immunotherapies; Recombinant fusion proteins; Single-domain antibodies
- Mechanism of Action Antibody-dependent cell cytotoxicity; T lymphocyte stimulants; Tumour necrosis factor receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Research Breast cancer; Lung cancer; Ovarian cancer; Pancreatic cancer; Testicular cancer; Thyroid cancer
Most Recent Events
- 16 Sep 2022 LEAD 472 is available for licensing as of 16 Sep 2022. https://leadartis.com/contact-us/
- 16 Sep 2022 LeadArtis has patent protections in the EU, prior to September 2022 (LeadArtis pipeline, September 2022)
- 16 Sep 2022 LeadArtis has pending patent applications in the EU, prior to September 2022 (LeadArtis pipeline, September 2022)